Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. It is developing fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura and Phase II clinical trials for IgA nephropathy; R348, a topical JAK/SYK inhibitor that is in Phase II clinical trials for the treatment of dry eye in ocular graft-versus-host disease; and two oncology product candidates in Phase I development. The company has a license agreement with AstraZen...
1180 Veterans Boulevard
South San Francisco, CA 94080
Founded in 1996
Rigel Pharmaceuticals Mulls Acquisitions
Aug 18 15
Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL) is seeking acquisitions. Rigel Pharmaceuticals announced a follow-on equity offering in the amount of $30.00 million and said in prospectus, “We may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own, although we have no commitments or agreements with respect to any acquisitions as of the date of this prospectus supplement.”
Rigel Pharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 4 15
Rigel Pharmaceuticals, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported contract revenues from collaborations of $5,184,000, which was all related to collaboration with Bristol-Myers Squibb. It was comprised of $4.8 million of amortization of the $30 million upfront payment and $350,000 of research reimbursement. Loss from operations was $13,974,000 compared with $25,456,000 for the same period a year ago. Net loss was $13,912,000 or $0.16 per basic and diluted share compared with $25,391,000 or $0.29 per basic and diluted share for the same period a year ago.
For the six months, the company reported contract revenues from collaborations of $7,362,000. Loss from operations was $32,215,000 compared with $47,841,000 for the same period a year ago. Net loss was $32,105,000 or $0.36 per basic and diluted share compared with $47,694,000 or $0.54 per basic and diluted share for the same period a year ago.
Rigel Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 04, 2015
Jul 28 15
Rigel Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 04, 2015